Compare AbCellera Biologics Inc (ABCL) vs Invesco Preferred ETF (PGX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Invesco Preferred ETF — how do they compare? AbCellera Biologics Inc trades at $7.15 (market cap $2.35B), while Invesco Preferred ETF trades at $10.85. The key difference: AbCellera Biologics Inc is trading nearer its 52-week high, Invesco Preferred ETF nearer its low. Which is the better fit depends on your goals.
| ABCL | PGX | |
|---|---|---|
Market Cap | $2.35B | — |
Sector | Health | — |
52-Week High | $8.12 | $11.87 |
52-Week Low | $2.78 | $10.82 |
Enterprise Value | $1.99B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
PGX trades at $10.88, showing no change over the past 24 hours. The technical outlook is bearish, with moving averages indicating a downtrend and oscillators neutral. The company recently announced the sale of its Golden Sidewalk Project to Kenorland Exploration Ltd. on June 18, 2026, as per GlobeNewsWire.
The outlook for PGX is cautious due to bearish technical signals and negative sentiment from financial media. Risks include poor returns and limited downside protection highlighted by Seeking Alpha on May 5, 2026. Investment opportunities may hinge on successful asset sales and future strategic shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Invesco Preferred ETF
The fund generally will invest at least 80% of its total assets in the components of the index. Strictly in accordance with its guidelines and mandated procedures, ICE Data Indices, LLC selects securities for the index, which is a market capitalization-weighted index designed to measure the performance of the fixed rate US dollar-denominated preferred securities market.
Read more on PGX →
